Fall 2018 Seminar Series - 09/17/18 Hammond





Stanley Katz Lecture


Professor Paula Hammond 

Massachusetts Institute of Technology 


Monday, September 17, 2018

Seminar will be held in ST-160 (Lecture Hall) at 2:00 PM

Reception: 3:00 – 4:00 PM in Steinman Hall, Exhibit Room – 1st Floor




Layer-by-layer assembly provides an approach that allows complementary secondary interactions to generate a stable thin film coating that can contain a broad range of molecular and macromolecular systems. We have utilized this method to develop thin films that can deliver proteins and biologic drugs such as growth factors with highly preserved activity from surfaces with sustained release periods of several days; manipulation of the film composition can lead to simultaneous or sequential release of different components, resulting in highly tunable multi-agent delivery (MAD) nanolayered release systems for cancer nanoparticle, tissue engineering, biomedical device, and wound healing applications.

This approach can be applied to a range of nanomaterials that are of interest for cancer therapies, from solid nanocrystals that can act as imaging systems to nanometer scale drug containers such as liposomes or polymeric nanoparticles. This kind of approach offers the promise of delivery of a cascade of chemotherapy drugs in sequence, thus allowing for optimized combination therapy of synergistic drugs with therapeutic molecules such as siRNA. The generation of LbL nanoparticles that can directly target a specific tissues such as metastatic tumors, the lungs, or other key organs is dependent on the nature of the outer LbL layer, and the biodistribution of the nanoparticle is highly dependent on net surface charge, degree of hydration, and type of polyelectrolyte bilayer pair that is adsorbed as the final layers on the nanoparticle.  

Recent work in which these nanoparticle systems are designed for optimized uptake by advanced serous ovarian cancer cells will be discussed, and the use of these approaches to deliver combination siRNA/ chemotherapy or drug inhibitor combination therapies or to generate imaging systems and theranostic nanoparticles will be addressed. The potential to target other tissues using designed nanoplex systems is discussed, in particular for the case of targeting cartilage to address the early stages of post-traumatic osteoarthritis. The manipulation of outer surface charge and polymer chain functionality, as well as the ability to design these layered nanoscale complexes to respond to micro-environment cues to achieve controlled biodistribution and uptake to targeted cells in vivo will be described.

Professor Paula T. Hammond is the David H. Koch Chair Professor of Engineering at the Massachusetts Institute of Technology, and the Head of the Department of Chemical Engineering. She is a member of MIT’s Koch Institute for Integrative Cancer Research, the MIT Energy Initiative, and a founding member of the MIT Institute for Soldier Nanotechnology. She recently served as the Executive Officer (Associate Chair) of the Chemical Engineering Department (2008-2011).

The core of her work is the use of electrostatics and other complementary interactions to generate functional materials with highly controlled architecture.  Her research in nanomedicine encompasses the development of new biomaterials to enable drug delivery from surfaces with spatio-temporal control. She also investigates novel responsive polymer architectures for targeted nanoparticle drug and gene delivery, and has developed self-assembled materials systems for electrochemical energy devices.

Professor Paula Hammond was elected into the National Academy of Engineering in 2017. She was elected into the National Academy of Medicine in 2016, and into the 2013 Class of the American Academy of Arts and Sciences. She is also the recipient of the 2013 AIChE Charles M. A. Stine Award, which is bestowed annually to a leading researcher in recognition of outstanding contributions to the field of materials science and engineering, and the 2014 AIChE Alpha Chi Sigma Award for Chemical Engineering Research. She was selected to receive the Department of Defense Ovarian Cancer Teal Innovator Award in 2013, which supports a single visionary individual from any field principally outside of ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research.